News & Updates

Treatment with tirzepatide 15 mg/week results in a 33-percent reduction in the risk of major adverse cardiovascular events (MACE), results of a meta-analysis have shown. Moreover, its efficacy is consistent across individuals with or without obesity.

The use of tirzepatide appears to reduce decline in kidney function, prevent albuminuria progression, and lower the risk of the composite kidney outcome compared with dulaglutide in patients with type 2 diabetes (T2D), atherosclerotic cardiovascular disease (ASCVD), and very high-risk chronic kidney disease (CKD), reports a study presented at Kidney Week 2025.

Treatment with semaglutide helps reduce kidney fat and enhance glomerular haemodynamic in adult patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), as shown in the REMODEL trial.

Diabetes is frequently understood as a “sugar problem” due to consumption of sweet foods and beverages, pointing to a limited perspective.